
Listeria-Based Therapeutic Cancer Vaccine for MelanomaAward last edited on: 5/18/11
Sponsored Program
SBIRAwarding Agency
NIH : NCITotal Award Amount
$271,570Award Phase
2Solicitation Topic Code
-----Principal Investigator
Dirk G BrockstedtCompany Information
Aduro BioTech Inc (AKA: Nanotx Corporation~Oncologic Inc)
626 Bancroft Way Suite 3c
Berkeley, CA 94710
Berkeley, CA 94710
(510) 848-4400 |
bd@adurobiotech.com |
www.adurobiotech.com |
Location: Single
Congr. District: 12
County: Alameda
Congr. District: 12
County: Alameda
Phase I
Contract Number: 1R43CA153669-01A1Start Date: 9/21/10 Completed: 8/31/12
Phase I year
2010Phase I Amount
$200,763Public Health Relevance:
The incidence of melanoma is increasing at an alarming rate and yet for advanced or metastatic disease no effective treatments are available. It has been appreciated that the patient's own immune system plays a role in the control of this disease. In fact, spontaneous regressions are more frequently reported in melanoma compared to other cancers and these regressions correlate with an immune infiltrate at the site of the primary tumor. Recent advances in immunotherapy and encouraging results from a Phase 3 clinical trial demonstrating increased progression free survival suggest that therapeutic vaccines which induce multi- functional T cell immunity may be effective for the treatment of advanced or metastatic melanoma. The overall goal of this proposal is to develop a therapeutic vaccine for melanoma that is based on inactivated strains of recombinant Listeria monocytogenes expressing melanoma-associated antigens.
Thesaurus Terms:
Phase II
Contract Number: 5R43CA153669-02Start Date: 9/21/10 Completed: 8/31/12
Phase II year
2011Phase II Amount
$70,807Public Health Relevance:
The incidence of melanoma is increasing at an alarming rate and yet for advanced or metastatic disease no effective treatments are available. It has been appreciated that the patient's own immune system plays a role in the control of this disease. In fact, spontaneous regressions are more frequently reported in melanoma compared to other cancers and these regressions correlate with an immune infiltrate at the site of the primary tumor. Recent advances in immunotherapy and encouraging results from a Phase 3 clinical trial demonstrating increased progression free survival suggest that therapeutic vaccines which induce multi- functional T cell immunity may be effective for the treatment of advanced or metastatic melanoma. The overall goal of this proposal is to develop a therapeutic vaccine for melanoma that is based on inactivated strains of recombinant Listeria monocytogenes expressing melanoma-associated antigens.